Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Molecular and Cellular Biomedical Sciences (MCBS) Jurnal Farmasi Higea
Dwiyatna, Surya
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
REVIEW ARTIKEL: EFIKASI, KEAMANAN, DAN DURASI PENGGUNAAN ANTIPLATELET GOLONGAN P2Y12 INHIBITOR PADA PASIEN SINDROM KORONER AKUT Yustiana, Yustiana; Suharjono, Suharjono; Dwiyatna, Surya; Atmajani, Wanudya
Jurnal Farmasi Higea Vol 16, No 1 (2024)
Publisher : STIFARM Padang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52689/higea.v16i1.590

Abstract

Sindroma koroner akut (SKA), termasuk unstable angina (UA) dan infark miokard (IM) merupakan manifestasi penyakit jantung koroner. Penyakit jantung koroner merupakan penyebab kematian terbesar pada kasus kardiovaskular sehingga diperlukan penanganan dan terapi yang adekuat. Terapi antiplatelet merupakan terapi utama dalam manajemen penanganan sindroma koroner akut. Dual antiplatelet therapy (DAPT) adalah standar terapi da SKA. Antiplatelet golongan P2Y12 inhibitor merupakan salah satu komponen penting dalam DAPT. Adanya risiko perdarahan dan kejadian iskemia yang dapat terjadi selama terapi dengan P2Y12 inhibitor membuat pemilihan P2Y12 inhibitor menjadi suatu yang krusial. Pemilihan jenis obat dan durasi antiplatelet P2Y12 inhibitor tidak hanya mempertimbangkan efikasi, seperti MACE, tetapi juga perlu mempertimbangkan keamanan pasien, seperti kejadian, major bleeding, dan kejadian iskemia. Review artikel ini akan membahas terkait efikasi, keamanan, serta durasi dari penggunaan P2Y12 inhibitor pada pasien SKA berdasarkan bukti-bukti klinis.
Mechanism of Actions, Efficacy, and Long-term Use of Steroids in Autoimmune Hemolytic Anemia (AIHA) Yulistiani, Yulistiani; Dwiyatna, Surya; Utomo, Febriansyah Nur
Molecular and Cellular Biomedical Sciences Vol 7, No 3 (2023)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v7i3.345

Abstract

Autoimmune hemolytic anemia (AIHA) is a rare condition in which autoantibodies cause the loss of red blood cells. Steroids have been used to treat several illnesses, including AIHA. For now, steroids remain as the first line of treatment for AIHA. In AIHA, especially warm AIHA (wAIHA), steroids suppress autoantibody production and downregulate Fcγ receptors' expression on monocytes to prevent hemolysis. The type of steroids chosen for first-line therapy for wAIHA in pediatrics and adults are Prednisone (Prednisolone) and Methylprednisolone. At the same time, Dexamethasone is used as an alternative treatment in AIHA. Steroids show better therapeutic outcomes in the first 2-3 weeks of administration, but the proportion of patients who remain in remission after steroid discontinuation are still quite low. Long-term administration of steroids may affect bone, blood glucose metabolism, and hypothalamic-pituitary-adrenal axis (HPAA). However, steroids which have a linear pharmacokinetic profile, intermediate-acting glucocorticoids such as Prednisone (Prednisolone) or Methylprednisolone, and also tapering dose of steroids after 2-4 weeks administration will be safe for long term use as AIHA treatment.Keywords: steroids, glucocorticoid, corticosteroid, autoimmune hemolytic anemia, AIHA, mechanism of action, efficacy
Co-Authors Atmajani, Wanudya Suharjono, Suharjono Utomo, Febriansyah Nur Yulistiani Yulistiani, Yulistiani Yustiana Yustiana, Yustiana